24 completed. 24 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 24 | Completed 24 |
| Phase 2 | 2 | Completed 2 |
Follow Eylea: new trials by email Literature Review of Eylea trials Research Report on Eylea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema CT-P42, Eylea - Diabetic Macular Edema (DME) | Phase 3 | Completed | Celltrion | 348 | 2021-07-22 | 2023-12-05 |
| A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) KSI-301, Aflibercept, Sham Procedure - Wet Age-related Macular Degeneration | Phase 3 | Completed | Kodiak Sciences Inc | 557 | 2021-06-23 | 2024-07-03 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion Faricimab, Aflibercept, Sham Procedure - Macular Edema, Central Retinal Vein Occlusion | Phase 3 | Completed | Hoffmann-La Roche | 729 | 2021-03-02 | 2024-08-06 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion Faricimab, Aflibercept, Sham Procedure - Macular Edema, Branch Retinal Vein Occlusion | Phase 3 | Completed | Hoffmann-La Roche | 553 | 2021-03-02 | 2024-08-06 |
| A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) KSI-301, Aflibercept, Sham Procedure - Macular Edema, Retinal Vein Occlusion | Phase 3 | Completed | Kodiak Sciences Inc | 568 | 2020-09-25 | 2024-06-26 |
| Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration Brolucizumab 6mg, Aflibercept 2 mg - Neovascular Age-Related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 397 | 2019-11-29 | 2024-12-09 |
| Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) Brolucizumab 6 mg, Aflibercept 2 mg - Age-related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 734 | 2019-09-25 | 2024-10-09 |
| To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema Brolucizumab, Aflibercept - Diabetic Macular Edema | Phase 3 | Completed | Novartis Pharmaceuticals | 266 | 2019-08-23 | 2024-10-09 |
| Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Brolucizumab, Aflibercept - Diabetic Macular Edema | Phase 3 | Completed | Novartis Pharmaceuticals | 517 | 2019-07-17 | 2022-08-12 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) Faricimab, Aflibercept, Sham Procedure - Wet Macular Degeneration | Phase 3 | Completed | Hoffmann-La Roche | 658 | 2019-03-11 | 2025-07-11 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) Faricimab, Aflibercept, Sham Procedure - Wet Macular Degeneration | Phase 3 | Completed | Hoffmann-La Roche | 671 | 2019-02-19 | 2025-07-23 |
| A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema Aflibercept, Faricimab, Sham Procedure - Diabetic Macular Edema | Phase 3 | Completed | Hoffmann-La Roche | 951 | 2018-10-09 | 2025-07-11 |
| A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) Aflibercept, Faricimab, Sham Procedure - Diabetic Macular Edema | Phase 3 | Completed | Hoffmann-La Roche | 940 | 2018-09-05 | 2025-07-11 |
| Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME) MYL-1701P, Eylea - Diabetic Macular Edema | Phase 3 | Completed | Mylan Pharmaceuticals Inc | 355 | 2018-08-23 | 2023-03-07 |
| A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Brolucizumab, Aflibercept - Diabetic Macular Edema | Phase 3 | Completed | Novartis Pharmaceuticals | 360 | 2018-07-27 | 2025-01-07 |
| Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Brolucizumab, Aflibercept - Diabetic Macular Edema | Phase 3 | Completed | Novartis Pharmaceuticals | 566 | 2018-07-23 | 2023-01-30 |
| DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group - Diabetic Macular Edema | Phase 3 | Completed | Jaeb Center for Health Research | 270 | 2017-12-07 | 2026-10-01 |
| Anti-VEGF vs. Prompt Vitrectomy for VH From PDR 2-mg Intravitreous Aflibercept Injection, Prompt Vitrectomy Plus Panretinal Photocoagulation - Proliferative Diabetic Retinopathy, Vitreous Hemorrhage | Phase 2 / Phase 3 | Completed | Jaeb Center for Health Research | 205 | 2016-11-01 | 2021-04-20 |
| Anti-VEGF Treatment for Prevention of PDR/DME Prompt Sham, Prompt aflibercept, Deferred laser - Diabetic Retinopathy, Diabetic Macular Edema | Phase 3 | Completed | Jaeb Center for Health Research | 399 | 2016-01-01 | 2023-06-18 |
| Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) aflibercept, bevacizumab - Central Retinal Vein Occlusion | Phase 3 | Completed | The Emmes Company, LLC | 362 | 2014-09-01 | 2021-06-22 |
Showing 20 of 24. Sign in to see all of them.
Macular Edema (6) · Vision Disorders (5) · Wet Macular Degeneration (5) · Diabetic Retinopathy (4) · Eye Diseases (4) · Macular Degeneration (4) · Retinal Degeneration (4) · Retinal Diseases (4) · Retinal Vein Occlusion (4) · Vision, Low (2) · Blindness (1) · Choroidal Neovascularization (1) · Geographic Atrophy (1) · Glaucoma (1) · Vitreous Hemorrhage (1)
Hoffmann-La Roche (6) · Novartis Pharmaceuticals (6) · Jaeb Center for Health Research (4) · Kodiak Sciences Inc (2) · Celltrion (1) · Centre Hospitalier Intercommunal Creteil (1) · Instituto de Olhos de Goiania (1) · Mylan Pharmaceuticals Inc (1) · Ophthalmic Consultants of Long Island (1) · The Emmes Company, LLC (1)
United States (18) · Germany (10) · Hungary (10) · France (9) · Italy (9) · Poland (9) · Spain (9) · Israel (8) · Russia (8) · Canada (7) · Czechia (7) · Argentina (6) · Australia (6) · Austria (6) · China (6)
Pablo Velazquez-Martin, MD (2) · Adam Glassman, MS (1) · Andrew Antoszyk, MD (1) · Carl Baker, MD (1) · Eric Souied, MD (1) · Glenn L Stoller, MD (1) · Ingrid U Scott, M.D., M.P.H. (1) · Jennifer K. Sun, MD, MPH (1) · Joao J Nassaralla, MD PhD (1)
PMID 35085502, PMID 35085503, PMID 36246184, PMID 36246941, PMID 36897413, PMID 37294433, PMID 37585454, PMID 38158159, PMID 38280653, PMID 38382813, PMID 38758639, PMID 38852921, PMID 40668667, PMID 41534798, PMID 41712218, PMID 42753135, PMID 42771326, PMID 28492910, PMID 30681643, PMID 31037289, PMID 31169862, PMID 31600368, PMID 33320223, PMID 33415354, PMID 33784735, PMID 33956075, PMID 34709363, PMID 35461831, PMID 35833805, PMID 36584835, PMID 36749332, PMID 36912792, PMID 37220815, PMID 37943541, PMID 37955955, PMID 37971723, PMID 37972038, PMID 39264599, PMID 39580145, PMID 40107501, PMID 40496217, PMID 40879891, PMID 41961203, PMID 42005909, PMID 42054088, PMID 42104207, PMID 42373197, PMID 42492647
2017 (4), 2018 (2), 2019 (2), U10EY023521 (1), U10EY023529 (1), U10EY023533 (1)